NEW YORK ─ Bio-Me and Siolta Therapeutics on Monday announced that they have entered into a collaboration and marketing agreement to develop a rapid diagnostic test for newborns at risk of developing allergy and asthma later in life.
Siolta will provide samples and insights into key criteria to Bio-Me as part of the deal.
The test would also help San Carlos, California-based Siolta identify and monitor patients eligible for its biotherapeutic therapy currently under development, the firms said.
Financial and other terms of the agreement were not disclosed.